Abstract
The protein kinase GCN2 is activated in amino acid-starved cells on binding of uncharged tRNA to a histidyl-tRNA synthetase (HisRS)-related domain. We isolated two point mutations in the protein kinase (PK) domain, R794G and F842L, that permit strong kinase activity in the absence of tRNA binding. These mutations also bypass the requirement for ribosome binding, dimerization, and association with the GCN1/GCN20 regulatory complex, suggesting that all of these functions facilitate tRNA binding to wild-type GCN2. While the isolated wild-type PK domain was completely inert, the mutant PK was highly active in vivo and in vitro. These results identify an inhibitory structure intrinsic to the PK domain that must be overcome on tRNA binding by interactions with a regulatory region, most likely the N terminus of the HisRS segment. As Arg 794 and Phe 842 are predicted to lie close to one another and to the active site, they may participate directly in misaligning active site residues. Autophosphorylation of the activation loop was stimulated by R794G and F842L, and the autophosphorylation sites remained critical for GCN2 function in the presence of these mutations. Our results imply a two-step activation mechanism involving distinct conformational changes in the PK domain.
Keywords: eIF2α kinase, GCN2, regulation, translation, tRNA
Protein synthesis can be down-regulated by phosphorylation of Ser 51 in the α-subunit of translation initiation factor 2 (eIF2α). The eIF2 forms a ternary complex with GTP and methionyl-tRNAMet (Met-tRNAiMet) that transfers Met-tRNAiMet to the small ribosomal subunit. Phosphorylated eIF2 inhibits its own guanine nucleotide exchange factor, eIF2B, impeding formation of the ternary complex and subsequent steps in the pathway. The eIF2α kinase GCN2 is activated by amino acid starvation (Hinnebusch 1996; Harding et al. 2000) and was first identified as a translational inducer of GCN4, a transcriptional activator of amino acid biosynthetic enzymes in budding yeast. Four short upstream open reading frames (uORFs) in the GCN4 mRNA leader underlie a specialized reinitiation mechanism that stimulates GCN4 translation in response to a moderate reduction in ternary complex levels. Thus, GCN2 can induce GCN4, and thereby replenish amino acid pools, without provoking a general shut-off of translation (Hinnebusch 1996).
GCN2 is activated in amino acid-starved yeast cells through binding of uncharged tRNA to a region related to histidyl-tRNA synthetase (HisRS) (Fig. 1A; Wek et al. 1989). Mutations in conserved residues involved in tRNA binding by authentic synthetases (the m2 motif) destroyed tRNA binding in vitro and impaired GCN2 function in vivo (Wek et al. 1995; Dong et al. 2000). Starvation for any amino acid activates GCN2 (Wek et al. 1995) and consistently, purified GCN2 bound various uncharged tRNAs with similar affinities, but bound more tightly to uncharged versus charged tRNAPhe (Dong et al. 2000).
The extreme C terminus of GCN2 (C-term) is also essential for GCN2 function (Wek et al. 1990). The C-term promotes tRNA binding to the HisRS domain (Dong et al. 2000) and is required for ribosome association in cell extracts (summarized in Fig. 1A; Zhu and Wek 1998). While the C-term, HisRS, and protein kinase (PK) domains all have dimerization activities, only the C-term is critical for dimerization by full-length GCN2 (Qiu et al. 1998, 2001). The conserved N terminus of GCN2 is the binding domain for the GCN1/GCN20 complex (Garcia-Barrio et al. 2000), a known activator of GCN4 translation. The GCN1/GCN20 complex also has ribosome binding activity (Marton et al. 1997) and may interact with the decoding (A) site on the ribosome. We have proposed that GCN1/GCN20 facilitates the transfer of uncharged tRNA from the A site to GCN2 (Sattlegger and Hinnebusch 2000).
The isolated C-term domain can physically interact with the HisRS and PK domains (summarized in Fig. 1A). Interestingly, the C-term–PK interaction was weakened by the GCN2c-E803V mutation in the PK domain (Fig. 1A), which confers constitutive activation of GCN2 function in vivo (Qiu et al. 2001). The fact that E803V also increased the affinity of GCN2 for tRNA implied that tRNA binding is impeded by the PK–C-term interaction, such that tRNA binding would normally occur only in starved cells when uncharged tRNA accumulates. The C-term–PK interaction might inhibit PK activity as well, in which case bound tRNA would dissolve this autoinhibitory interaction. The N-terminal portion of the HisRS region (HisRS-N) also interacts with the PK domain (Fig. 1A; Qiu et al. 2001), and the HisRS-N segment stimulates kinase function independently of its role in tRNA binding or dimerization. Thus, it appears that the HisRS-N region remains engaged with the PK domain in the tRNA-bound state to promote kinase activation.
Here we present compelling evidence that the PK domain itself contains an autoinhibitory function. We isolated two mutations in the PK domain (R794G and F842L) as intragenic suppressors of the tRNA binding defect of the m2 mutation in the HisRS domain. Remarkably, these mutations bypass the requirement for all domains flanking the PK moiety for strong kinase activity in vivo and in vitro. The substituted residues are predicted to be close to one another and to the active site in the folded PK domain. Hence, the wild-type residues most likely distort the alignment of active site groups. Our results imply that the PK domain in GCN2 is intrinsically defective and must interact with the flanking HisRS domain on tRNA binding to achieve an active conformation.
Results
Previously described GCN2c products require the m2 motif for kinase activity
Point mutations in motif 2 of the HisRS-like domain in GCN2 (gcn2-m2, Fig. 1A) abolish tRNA binding in vitro and inactivate GCN2 function in vivo (Wek et al. 1995). Numerous mutations that activate GCN2 constitutively (GCN2c alleles) have been isolated in the PK, HisRS-like, and C-term domains (Fig. 1A; Wek et al. 1990; Ramirez et al. 1992). To determine whether these GCN2c products require tRNA binding for activation, we combined the m2 substitutions with each of the plasmid-borne GCN2c alleles shown in Figure 1A and analyzed the resulting constructs in a gcn2Δ strain. GCN2 function was assessed by measuring growth on medium containing 3-aminotriazole (3AT), an inhibitor of histidine biosynthesis, or on medium containing the amino acid analogs 5-fluorotryptophan (5FT) and 1,2,4-triazolealanine (TRA) (Ramirez et al. 1992). Growth on 3AT medium requires GCN2-dependent derepression of GCN4 and its target genes in the histidine biosynthetic pathway. GCN2c strains are more resistant than wild-type to 5FT and TRA because they produce constitutively derepressed levels of tryptophan and histidine biosynthetic enzymes (Ramirez et al. 1992).
None of the GCN2c-m2 mutants grew on 5FT/TRA medium and only one (GCN2c-M788V-m2) grew weakly on 3AT medium compared to wild type (data not shown). Hence, the constitutive activation of all previously described GCN2c proteins is strongly dependent on tRNA binding. This conclusion was confirmed for the GCN2c-M788V allele by measuring expression of a GCN2-dependent HIS4-lacZ reporter. The GCN2c-M788V-m2 strain showed repressed levels of HIS4-lacZ in nonstarved cells, comparable to that seen in GCN2, gcn2-m2, or gcn2Δ strains, whereas the parental GCN2c-M788V strain had ∼fourfold greater HIS4-lacZ activity (Table 1, rows 1–5).
Table 1.
|
Plasmid
|
Alleles
|
Growth on SC
|
Growth on 3-AT
|
HIS4-lacZ expression (Units of β-gal activity)
|
Relative GCN2 protein level
|
---|---|---|---|---|---|---|
1 | pRS316 | Vector | +++ | − | 160 | None |
2 | p722 | GCN2 | ++++ | +++ | 170 | 100 |
3 | p299 | gcn2-m2 | +++ | − | 160 | ND |
4 | p912 | GCN2c-M788V | ++++ | +++ | 670 | 90 |
5 | pHQ928 | GCN2c-M788V-m2 | ++++ | + | 160 | 110 |
6 | pHQ1096 | GCN2c-R794G-m2 | + | ++ | 820 | 40 |
7 | pHQ1098 | GCN2c-F842L-m2 | + | ++ | 850 | 50 |
8 | pHQ1102 | GCN2c-R794G | −/+ | + | 1170 | 50 |
9 | pHQ1103 | GCN2c-F842L | −/+ | + | 1160 | 70 |
10 | pHQ1127 | GCN2Hyper b | Lethal | NA | NA | NA |
11 | pHQ1140 | GCN2Hyper-m2b | +/− | ++ | 1170 | 30 |
12 | pB9 | gcn2-T882A | ++++ | + | 160 | 70 |
13 | pB10 | gcn2-T887A | +++ | − | 160 | 50 |
14 | pHQ1251 | GCN2hyper-T882Ab | Lethal | NA | NA | NA |
15 | pHQ1252 | GCN2Hyper-T887Ab | ++++ | + | 540 | 60 |
16 | pHQ1253 | gcn2Hyper-T882A T887Ab | ++++ | − | 230 | 90 |
Transformants of gcn2Δ strain H1149 with the indicated plasmids were rated for growth on SC-Ura plates by scoring the average colony size during the transformation experiments. Growth on 3-AT plates was measured by replica-plating and scored qualitatively after 3 d of incubation. To measure HIS4-lacZ expression, the transformants were cultured in nonstarvation conditions as described in Materials and Methods and WCEs were prepared and assayed for β-galactosidase (β-gal) activity. The results shown are means calculated from three transformants. The β-gal activity is expressed as nanomoles of o-nitrophenyl-β-D-galactopyronoside hydrolyzed per minute per milligram of protein. The standard errors are less than 20%. The relative protein levels were determined by Western blot analysis of WCEs using GCN2 antibodies. The Western blot signals were quantified with a scanner (Silverscanner III) and NIH image software (version 1.61). ND, Not determined; NA, not applicable.
GCN2Hyper represents GCN2c-R794G-F842L.
Mutations R794G and F842L in the PK domain constitutively activate the gcn2-m2 product
We set out to isolate a new class of GCN2c mutations that would activate GCN2 independently of tRNA binding. As described in Materials and Methods, we identified the R794G and F842L mutations in the kinase domain as strong suppressors of the 3AT-sensitive (3ATs) phenotype of gcn2-m2. Both the GCN2c-R794G-m2 and GCN2c-F842L-m2 alleles also conferred resistance to 5FT/TRA (Fig. 1B) and derepression of HIS4-lacZ under nonstarvation conditions compared to GCN2 and gcn2-m2 (Table 1, rows 2, 3, 6, and 7). They also produced a slow-growth (Slg−) phenotype on complete (SC) medium (Fig. 1C), characteristic of highly activated GCN2c alleles (Ramirez et al. 1992). Removing the m2 mutations exacerbated both the Slg− phenotype (Fig. 1C) and derepression of HIS4-lacZ by R794G and F842L (Table 1, rows 6–9). Thus, although these mutations greatly reduce the requirement for tRNA binding, restoring motif 2 produced even greater kinase activity.
The allele containing both activating mutations plus m2 conferred a more severe growth defect and greater derepression of HIS4-lacZ than did the GCN2c-R794G-m2 and GCN2c-F842L-m2 alleles (Table 1, rows 6–7, 11), showing that R794G and F842L have cumulative activating effects. Indeed, combining F842L and R794G in the same allele with wild-type motif 2 produced a lethal phenotype (Table 1, row 10). The latter can be attributed to an intolerably high level of eIF2α phosphorylation because GCN2c-R794G-F842L had no phenotype in a strain expressing nonphosphorylatable eIF2α (alanine at position 51; data not shown). Henceforth, we refer to GCN2c-R794G-F842L as GCN2Hyper (for hyperactivated GCN2).
We confirmed that the activating mutations produce high-level phosphorylation of eIF2α under nonstarvation conditions. Because GCN2Hyper is lethal in the presence of wild-type eIF2α, we analyzed a mutant strain where eIF2B is resistant to inhibition by phosphorylated eIF2 because of a mutation in its δ-subunit (GCD2-K627T; Pavitt et al. 1997). Using antibodies that recognize eIF2α phosphorylated on Ser 51 (P-eIF2α) to probe whole cell extracts (WCEs), we found that eIF2α was phosphorylated in the GCN2c-R794G, GCN2c-F842L, and GCN2Hyper strains under nonstarvation conditions, whereas wild-type cells contained an appreciable amount of P-eIF2α only under starvation conditions (Fig. 1D).
The GCN2Hyper PK domain is active in the absence of flanking regulatory domains
We wished to determine whether the GCN2Hyper mutations overcome the requirement for the entire HisRS domain, as well as the ribosome-binding and dimerization functions of the C-term and the GCN1/GCN20 binding domain in the N terminus. To this end, we combined the GCN2Hyper mutations with deletions that remove different segments flanking the PK domain, culminating in a construct that contains only the core PK moiety (Fig. 2). The deletions in the constructs marked with asterisks (rows 3, 5, 6, and 8) destroyed GCN2 function when examined in the absence of the GCN2Hyper mutations, conferring 3AT-sensitivity in a gcn2Δ strain even on high-copy plasmids (data not shown). Remarkably, none of the deletions in Figure 2 inactivated kinase function when combined with the GCN2Hypermutations. The last two alleles complemented the 3ATS phenotype, and derepressed HIS4-lacZ expression above the wild-type level, only when introduced into the gcn2Δ strain on high-copy plasmids (Fig. 2). Nevertheless, the functionality of the last construct provides a striking demonstration that the GCN2Hyper mutations bypass the need for all regions flanking the PK domain for substantial kinase activity in vivo.
The products of the last three alleles shown in Figure 2 lack the C-term and, thus, should be defective for ribosome binding. To show that the GCN2Hyper mutations did not activate a cryptic ribosome binding activity in the PK domain, we confirmed that GCN2Hyper-Δ1536–1659 (row 6) and gcn2–Δ1536–1659 were equally defective for ribosome binding in WCEs (data not shown). Deletion of the C-term from GCN2Hyper also should abolish dimerization. However, we showed previously that the PK domain can dimerize more efficiently when all flanking regions are eliminated, allowing stable PK-PK dimers to form in vivo (Qiu et al. 1998). To determine whether R794G and F842L increase kinase activity by stimulating dimerization of the PK domain, we asked whether these mutations increase the formation of heterodimers by LexA- and HA-tagged PK domains coexpressed in the same cells. As shown in Figure 3A (left panel), ∼15% of a LexA fusion containing the C-terminal two-thirds of the kinase domain (LexA-‘PK[720–999]) was specifically coimmunoprecipitated with the HA-tagged PK domain (3xHA-PK[591–1010]). Importantly, the presence of the GCN2Hyper mutations in the LexA- and HA-tagged PK domain had no significant effect on the yield of heterodimers (Fig. 3A, right panel). The same conclusion was reached for analogous constructs containing larger PK segments encompassing residues 591–1010 (data not shown). We conclude that the GCN2Hyper mutations do not increase kinase activity by stimulating dimerization of the PK domain.
Deleting the GCN1/GCN20 binding domain at the N terminus of GCN2Hyperdid not eliminate its lethal phenotype (Fig. 2, row 4), suggesting that the GCN2Hyper mutations bypass the requirements for GCN1 and GCN20 in kinase activation. Confirming this prediction, we found that GCN2c-R794G and GCN2c-F842L conferred strong 3-AT-resistance in gcn1Δ, gcn20Δ, or gcn1Δ gcn20Δ strains, whereas the corresponding strains with wild-type GCN2 were 3ATs. Thus, GCN2c-R794G and GCN2c-F842L are highly active in the absence of GCN1 and GCN20. Consistently, the GCN2Hyper allele retained its lethal phenotype in the gcn1Δ gcn20Δ strain (data not shown).
The core PK domain containing R794G F842L (PKHyper) is active in vitro
Because we could not detect the core PK fragment depicted in Figure 2 (row 8) with GCN2 antibodies, we constructed an allele encoding the same segment tagged at the N terminus with FLAG epitope under the control of a galactose-inducible promoter. This construct (FL-PKHyper) and the analogous one lacking the R794G and F842L mutations (FL-PK) were examined for their effects on cell growth and eIF2α phosphorylation in a gcn2Δ strain. Transformants expressing FLAG-tagged full-length GCN2 from the GAL promoter (FL-GCN2) or native GCN2 were analyzed in parallel. On medium where the GAL promoter is repressed, all transformants had similar growth rates. On galactose medium, the FL-PKHyper construct was very toxic, whereas FL-PK, FL-GCN2, and GCN2 had no effect on cell growth. The FL-PKHyper construct did not inhibit growth in an isogenic strain expressing nonphosphorylatable eIF2α (data not shown). Consistently, phosphorylated eIF2α was produced constitutively in cells expressing FL-PKHyper but was undetectable in cells expressing FL-PK or FL-PKHyper-K628R (with a nonfunctional kinase subdomain II) (Fig. 3B, lanes 3–8). As expected, cells expressing FL-GCN2 contained P-eIF2α only under starvation conditions (Fig. 3B, lanes 9 and 10). Thus, the wild-type PK domain (FL-PK) is completely inactive, whereas FL-PKHyper has high-level kinase activity in vivo.
To demonstrate this last point in vitro, we purified the FLAG-tagged proteins and conducted kinase assays using a recombinant form of eIF2α (eIF2α–ΔC) and [γ-32P]ATP as substrates. Phosphorylation of eIF2α–ΔC was readily detected using only 5 nM FL-PKHyper, whereas no P-eIF2α–ΔC was detected in reactions containing 80-fold more FL-PK (Fig. 3C, lanes 2 and 8). These results prove that the wild-type PK domain is intrinsically defective for eIF2α phosphorylation and that the R794G and F842L mutations overcome this defect in kinase function. We showed previously that the E803V mutation in the PK domain leads to constitutive phosphorylation of eIF2α in vivo and increases the tRNA binding activity of GCN2 (Dong et al. 2000). As indicated above, GCN2c-E803V was inactivated by the m2 mutation, suggesting that E803V activates GCN2 by increasing its affinity for tRNA rather than eliminating an inhibitory structure in the PK domain. Consistently, purified FL-PKE803V had barely detectable eIF2α kinase activity, at least 100 times lower than that of FL-PKHyper(Fig. 3C, lanes 13–15 vs. 10–12).
Autophosphorylation sites in the activation loop are required for GCN2Hyper activity
GCN2 autophosphorylates in vitro on two threonine residues in the activation loop of the PK domain, Thr 882 and Thr 887. Alanine substitutions at these positions reduced (T882A) or eliminated (T887A) GCN2 function in vivo (Romano et al. 1998). As phosphorylation of the activation loop is frequently associated with kinase activation (Johnson et al. 1996), we explored whether the GCN2Hyper mutations bypass the requirement for autophosphorylation of Thr 882 and Thr 887. As shown in Table 1, T887A eliminated the growth defect, but not the 3-AT-resistance and derepression of HIS4-lacZ conferred by GCN2Hyper (rows 10 and 15). Although T882A alone did not suppress the lethality of GCN2Hyper, it further inactivated GCN2Hyper-T887A, eliminating 3-AT resistance and HIS4-lacZ derepression (Table 1, rows 12–16). Thus, GCN2Hyper is strongly dependent on both autophosphorylation sites. Consistently, introducing T887A alone or both T882A and T887A into FL-PKHyper eliminated phosphorylation of eIF2α in vivo, whereas T882A alone led to a small reduction in eIF2α phosphorylation (Fig. 4A). The fact that FL-PKHyper-T887A is inactive whereas GCN2Hyper-T887A retains kinase activity in vivo (Table 1, row 15) is consistent with other results in Table 1 and Figure 2, indicating that the flanking domains enhance PK function in the GCN2Hyper protein.
We asked next whether GCN2 autophosphorylation is stimulated by the GCN2Hyper mutations. Using antibodies specific for GCN2 phosphorylated on Thr 882 to probe purified GCN2 proteins, we found that FL-GCN2Hyper contained 10- to 20-fold more phosphorylated Thr 882 (P-T882) than did FL-GCN2 (Fig. 4B). Consistently, FL-GCN2Hyper had >40-fold higher in vitro kinase activity than did FL-GCN2 (data not shown). As shown in Figure 4C, P-T882 was readily detected in purified FL-PKHyper, whereas no P-T882 was found in FL-PK. Hence, the wild-type core PK domain is incapable of autophosphorylating Thr 882 in the activation loop, and the GCN2Hyper mutations greatly stimulate autokinase activity. Our findings support the idea that autophosphorylation of the activation loop is a prerequisite for the eIF2α kinase function of GCN2, even when an inhibitory structure in the PK domain has been eliminated by the GCN2Hyper mutations.
Discussion
Having found that the activating mutation GCN2c-E803V weakened interaction between isolated PK and C-term segments (Qiu et al. 2001) and also stimulated tRNA binding by GCN2, we proposed that the PK–C-term interaction interferes with tRNA binding to the HisRS–C-term domains. This would prevent tRNA binding in nonstarved cells where uncharged tRNA concentrations are low. The PK–C-term interaction could also inhibit PK function by an autoinhibitory mechanism that would be released by tRNA binding (Dong et al. 2000). Our finding here that the GCN2-E803V-m2 allele was completely nonfunctional indicates that the weakened interaction between the C-term and PK domains produced by E803V is not sufficient for kinase activation, and that tRNA binding is still required. In fact, it is possible that the C-term has no autoinhibitory function and that C-term–PK association merely occludes tRNA binding contacts in the C-term. In this view, E803V simply allows tRNA binding and kinase activation to occur at low concentrations of uncharged tRNA. As all other previously described GCN2c alleles were impaired by the m2 mutation, they may activate GCN2 by this same mechanism.
The GCN2Hyper mutations described here provide a critical new element to our model, as they produce constitutive kinase activation in the absence of tRNA binding. When combined in the same polypeptide, the GCN2Hyper mutations allow the core PK domain to function efficiently under conditions where the wild-type PK domain is completely inert. The simplest explanation for this finding is that the wild-type PK domain is intrinsically defective due to an inhibitory structure involving residues Arg 794 and Phe 842. An important implication of this result is that GCN2 cannot be activated merely by dissociating all flanking regulatory regions from the PK domain; otherwise, the wild-type core PK domain would be active. Rather, the inhibitory structure in the PK domain must be overcome by a stimulatory interaction with another part of the protein.
Based on a sequence alignment of the GCN2 PK domain and protein kinase A (PKA), residues Arg 794 and Phe 842 in GCN2 correspond to Gly 126 and Leu 173 in PKA subdomains V and VIb. Gly 126 in PKA is near the end of the extended chain connecting the N- and C-terminal lobes of the kinase domain (just prior to helix D), whereas Leu 173 occurs in the middle of β-strand 7 near the deep cleft between the two lobes (Fig. 5). As the site of catalysis lies within this cleft, both residues are near the active site. In fact, the residue adjacent to Gly 126 in PKA helps in anchoring ATP and the peptide substrate to the active site, while Leu 173 is only two residues away from an invariant residue in the catalytic loop (Asn 171; Hanks and Hunter 1995b). Computer analysis of PKA (using WebLab ViewerLite 3.2) revealed that Gly 126 and Leu 173 are nearly as close to one another in the folded structure as adjacent residues in the polypeptide chain (Fig. 5). Based on these considerations, we predict that Arg 794 and Phe 842 play a direct role in distorting the GCN2 active site. Consistently, the GCN2Hyper mutations replace these residues with the exact amino acids (Gly and Leu, respectively) found at the equivalent positions in PKA, an intrinsically active kinase, and in a majority of other protein kinases (Hanks and Hunter 1995a).
The HisRS-N region is required for activation of GCN2 independently of its role in tRNA binding. The HisRS-N segment binds to the PK domain between residues 750 and 810 (Qiu et al. 2001), encompassing the predicted extended connector between the N- and C-lobes of the PK domain and including the inhibitory residue Arg 794. Thus, an attractive hypothesis is that association of the HisRS-N/tRNA complex with this surface of the PK domain alters the relative orientation of the kinase lobes in a way that overcomes the misalignment of active site groups imposed by wild-type residues Arg 794 and Phe 842.
Phosphorylation of the activation loop is frequently required for kinase activation. It is thought that the phosphorylated residue stabilizes a positively charged cluster and thereby promotes the correct orientation and electrostatic environment of the catalytic aspartate (Asp 166 in PKA; Fig. 5) and the proper relative orientation of the N- and C-lobes (Johnson et al. 1996). We found that the GCN2Hyper mutations did not bypass the requirement for the autophosphorylation sites in the GCN2 activation loop, as replacement of Thr 887 and Thr 882 with alanine almost completely inactivated GCN2Hyper. Replacement of Thr 887 alone was sufficient to inactivate the core kinase domain in FL-PKHyper. Based on these findings, we propose that phosphorylation of the activation loop occurs only after the inhibitory structure of the PK domain has been corrected by interaction with the HisRS-N/tRNA module. Consistently, Thr 882 was phosphorylated in the highly active FL-PKHyper protein but not in the inactive wild-type core PK construct. Presumably, autophosphorylation stimulates a critical conformational change in the PK domain beyond that produced by association with the HisRS-N/tRNA module. This model has similarities with a mechanism proposed for activation of CDK2 by cyclin, in which binding of cyclin A realigns the active site residues and relieves the steric block to substrate binding imposed by the PSTAIRE helix and activation loop. Phosphorylation of the activation loop is additionally required for full activation of CDK2 (Jeffrey et al. 1995; Johnson et al. 1996).
The fact that the GCN2Hyper mutations bypass the requirement for the N-terminal GCN1/GCN20 binding domain and the C-term, in addition to the HisRS domain, suggests that all of these domains are required for activation of GCN2 by uncharged tRNA. This conclusion supports our proposal that the GCN1/GCN20 complex interacts with the N terminus of GCN2, anchored to the ribosome through the C-term, to mediate transfer of uncharged tRNAs from the decoding site on the ribosome to the HisRS domain (Sattlegger and Hinnebusch 2000).
Materials and methods
Isolation of GCN2c-R794G and GCN2c-F842L
GCN2 plasmid pHQ644 was subjected to random mutagenesis in E. coli mutator strain XL1-Red (Strategene). BspEI–Asp718 fragments were isolated from the mutagenized pHQ644 and used to replace the corresponding fragment of plasmid p299 containing the gcn2-m2 allele (library I). Similarly, the Eco47III-NheI fragment of plasmid p299 was replaced with the corresponding fragments from mutagenized pHQ644 to produce library II. The two libraries were screened in gcn2Δ strain H1149 for 3-ATr transformants. Of 3.4 × 105 transformants obtained with library I, 24 clones showed a plasmid-dependent 3-ATR phenotype, while no such clones were isolated from library II. Twenty-two of the 24 plasmids isolated from the 3-ATR colonies had an A to G mutation at codon 794 (AGA to GGA), producing the R794G substitution. The remaining two plasmids contained a T to C mutation at codon 842 (TTT to CTT), generating F842L.
All other plasmids used in this work are listed in Table 2, and details of their construction are available on request. Strains H1149 (Wek et al. 1990) and HQY132 (Qiu et al. 1998) were described previously. Strain HQY346 is a GAL2 derivative of GP3299 (Pavitt et al. 1997).
Table 2.
Plasmid
|
Allele
|
Reference
|
---|---|---|
p722 | GCN2, CEN6, URA3 | Wek et al. 1990 |
p299 | gcn2-m2 in p722 backbone | Wek et al. 1995 |
p912 | GCN2c-M788V in p722 backbone | Ramirez et al. 1992 |
pB9 | gcn2-T882A, CEN4, URA3 | Romano et al. 1998 |
pB10 | gcn2-T887A, CEN4, URA3 | Romano et al. 1998 |
pHQ644 | GCN2, p722 derivative | Qiu et al. 2001 |
p630 | high copy GCN2, 2μ, RUA3 | Wek et al. 1990 |
pHQ433 | high copy LexA-′PK(720-999) in pEG202 backbone | Qiu et al. 1998 |
pHQ928 | GCN2-M788V-m2 in p722 backbone | This study |
pHQ1096 | GCN2-R794G-m2 in p722 backbone | This study |
pHQ1098 | GCN2-F842L-m2 in p722 backbone | This study |
pHQ1102 | GCN2-R794G in pHQ644 backbone | This study |
pHQ1103 | GCN2-F842L in pHQ644 backbone | This study |
pHQ1127 | GCN2Hyperin pHQ644 backbone | This study |
pHQ1131 | high copy Flag-6xHis-GCN2Hyper under GAL promoter in pEMBLyex4 | This study |
pHQ1139 | GCN2Hyper-Δ1536-1659 in pHQ644 backbone | This study |
pHQ1140 | GCN2Hyper-m2 in pHQ644 backbone | This study |
pHQ1143 | GCN2Hyper-Δ110-235 in pHQ644 backbone | This study |
pHQ1165 | GCN2Hyper-Δ3-567 in pHQ644 backbone | This study |
pHQ1173 | GCN2Hyper-Δ1247-1402 in pHQ644 backbone | This study |
pHQ1193 | GCN2Hyper-Δ1011-1659 in pHQ644 backbone | This study |
pHQ1211 | high copy GCN2Hyper-Δ1011-1659 in YEplac195 | This study |
pHQ1213 | high copy Flag-6xHis-PK(591-1010)Hyperunder GAL promoter in pEMBLyex4 | This study |
pHQ1220 | Flag-6xHis-PK(591-1010)Hyper in p722 backbone | This study |
pHQ1222 | high copy 3xHA-PK(591-1010)Hyper in p630 backbone | This study |
pHQ1223 | high copy Flag-6xHis-PK(591-1010) under GAL promoter in pEMBLyex4 | This study |
pHQ1235 | high copy LexA-′PK(720-999)Hyper in pEG202 backbone | This study |
pHQ1241 | high copy 3xHA-PK(591-1010) in p630 backbone | This study |
pHQ1242 | high copy Flag-6xHis-PK(591-1010)Hyper-K628R under GAL promoter in pEMBLyex4 | This study |
pHQ1247 | high copy Flag-6xHis-PK(591-1010)Hyper-T882A under GAL promoter in pEMBLyex4 | This study |
pHQ1248 | high copy Flag-6xHis-PK(591-1010)Hyper-T887A under GAL promoter in pEMBLyex4 | This study |
pHQ1249 | high copy Flag-6xHis-PK(591-1010)Hyper-T882A T887A under GAL promoter in pEMBLyex4 | This study |
pHQ1251 | GCN2Hyper-T882A in pHQ644 backbone | This study |
pHQ1252 | GCN2Hyper-T887A in pHQ644 backbone | This study |
pHQ1253 | GCN2Hyper-T882A T887A in pHQ644 backbone | This study |
pHQ1261 | high copy Flag-6xHis-PK(591-1010)E803V under GAL promoter in pEMBLyex4 | This study |
Biochemical methods
Transformants of HQY346 bearing the appropriate plasmids encoding Flag-, 6xHis-tagged GCN2 proteins were grown in SD medium to saturation, diluted into minimal medium with 2% galactose (SGal) and grown to OD600 = 3.0. Affinity purification of the tagged proteins was conducted essentially as described (Dong et al. 2000). In vitro kinase assays (Dong et al. 2000) and assays of HIS4-lacZ expression (Lucchini et al. 1984) were all done as described previously. The enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech) was used to detect immune complexes, and Western signals were quantified by video image densitometry using NIH Image 1.61 software. Phosphospecific antibodies against P-eIF2α (Biosource International) and polyclonal antibodies against eIF2α (CM-217) (Cigan et al. 1989), antibodies against GCN2 (Romano et al. 1998), and antibodies against LexA (Qiu et al. 1998) were described previously. Flag- or HA-tagged proteins were detected using FLAG (Sigma) and HA antibodies (Roche). Antibodies specific for GCN2 phosphorylated on Thr 882 were produced by Quality Controlled Biochemicals against a synthetic peptide corresponding to the GCN2 activation loop phosphorylated on Thr 882 (in single-letter code: CPGSSDNL[P-T882]SAI). The antibodies were preabsorbed with the nonphosphorylated peptide and affinity-purified with the phosphorylated peptide. In Western blot analysis, the antibodies reacted with FL-GCN2 (wild type) but not with FL-GCN2-T882A or catalytically inactive FL-GCN2-K628R.
Acknowledgments
We are indebted to Ron Wek for plasmid p299 and we thank Tom Dever for help with Weblab™ ViewerLite 3.2, valuable discussions, gifts of antibodies, and critical reading of the manuscript.
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 USC section 1734 solely to indicate this fact.
Footnotes
E-MAIL ahinnebusch@nih.gov; FAX (301) 496-6828.
Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.979402.
References
- Dong J, Qiu H, Garcia-Barrio M, Anderson J, Hinnebusch AG. Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell. 2000;6:269–279. doi: 10.1016/s1097-2765(00)00028-9. [DOI] [PubMed] [Google Scholar]
- Garcia-Barrio M, Dong J, Ufano S, Hinnebusch AG. Association of GCN1/GCN20 regulatory complex with the conserved N-terminal domain of eIF2a kinase GCN2 is required for GCN2 activation in vivo. EMBO J. 2000;19:1887–1899. doi: 10.1093/emboj/19.8.1887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hanks SK, Hunter T. The eukaryotic protein kinase superfamily. In: Hardie G, Hanks S, editors. The protein kinase facts book. San Diego, CA: Academic Press; 1995a. pp. 7–47. [Google Scholar]
- ————— The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J. 1995b;9:576–596. [PubMed] [Google Scholar]
- Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6:1099–1108. doi: 10.1016/s1097-2765(00)00108-8. [DOI] [PubMed] [Google Scholar]
- Hinnebusch AG. Translational control of GCN4: Gene-specific regulation by phosphorylation of eIF2. In: Hershey JWB, Mathews MB, Sonenberg N, editors. Translational control. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1996. pp. 199–244. [Google Scholar]
- Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995;376:313–320. doi: 10.1038/376313a0. [DOI] [PubMed] [Google Scholar]
- Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: Structural basis for regulation. Cell. 1996;85:149–158. doi: 10.1016/s0092-8674(00)81092-2. [DOI] [PubMed] [Google Scholar]
- Knighton DR, Zheng J, Ten Eyck LF, Xuong NH, Taylor SS, Sowadski JM. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 1991;253:407–414. doi: 10.1126/science.1862342. [DOI] [PubMed] [Google Scholar]
- Lucchini G, Hinnebusch AG, Chen C, Fink GR. Positive regulatory interactions of the HIS4 gene of Saccharomyces cerevisiae. Mol Cell Biol. 1984;4:1326–1333. doi: 10.1128/mcb.4.7.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Marton MJ, Aldana CRVd, Qiu H, Chakraburtty K, Hinnebusch AG. Evidence that GCN1 and GCN20, translational regulators of GCN4, function on enlongating ribosomes in activation of the eIF2a kinase GCN2. Mol Cell Biol. 1997;17:4474–4489. doi: 10.1128/mcb.17.8.4474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pavitt GD, Yang W, Hinnebusch AG. Homologous segments in three subunits of the guanine nucleotide exchange factor eIF2B mediate translational regulation by phosphorylation of eIF2. Mol Cell Biol. 1997;17:1298–1313. doi: 10.1128/mcb.17.3.1298. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qiu H, Dong J, Hu C, Francklyn CS, Hinnebusch AG. The tRNA-binding moiety in GCN2 contains a dimerization domain that interacts with the kinase domain and is required for tRNA binding and kinase activation. EMBO J. 2001;20:1425–1438. doi: 10.1093/emboj/20.6.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Qiu H, Garcia-Barrio MT, Hinnebusch AG. Dimerization by translation initiation factor 2 kinase GCN2 is mediated by interactions in the C-terminal ribosome-binding region and the protein kinase domain. Mol Cell Biol. 1998;18:2697–2711. doi: 10.1128/mcb.18.5.2697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ramirez M, Wek RC, Vazquez de Aldana CR, Jackson BM, Freeman B, Hinnebusch AG. Mutations activating the yeast eIF-2a kinase GCN2: Isolation of alleles altering the domain related to histidyl-tRNA synthetases. Mol Cell Biol. 1992;12:5801–5815. doi: 10.1128/mcb.12.12.5801. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, Herring C, Mathews MB, Qin J, Hinnebusch AG. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2a kinases PKR and GCN2. Mol Cell Biol. 1998;18:2282–2297. doi: 10.1128/mcb.18.4.2282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sattlegger E, Hinnebusch AG. Separate domains in GCN1 for binding protein kinase GCN2 and ribosomes are required for GCN2 activation in amino acid-starved cells. EMBO J. 2000;19:6622–6633. doi: 10.1093/emboj/19.23.6622. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wek RC, Jackson BM, Hinnebusch AG. Juxtaposition of domains homologous to protein kinases and histidyl-tRNA synthetases in GCN2 protein suggests a mechanism for coupling GCN4 expression to amino acid availability. Proc Natl Acad Sci. 1989;86:4579–4583. doi: 10.1073/pnas.86.12.4579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wek RC, Ramirez M, Jackson BM, Hinnebusch AG. Identification of positive-acting domains in GCN2 protein kinase required for translational activation of GCN4 expression. Mol Cell Biol. 1990;10:2820–2831. doi: 10.1128/mcb.10.6.2820. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wek SA, Zhu S, Wek RC. The histidyl-tRNA synthetase-related sequence in the eIF-2a protein kinase GCN2 interacts with tRNA and is required for activation in response to starvation for different amino acids. Mol Cell Biol. 1995;15:4497–4506. doi: 10.1128/mcb.15.8.4497. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zhu S, Wek RC. Ribosome-binding domain of eukaryotic initiation factor-2 kinase GCN2 facilitates translation control. J Biol Chem. 1998;273:1808–1814. doi: 10.1074/jbc.273.3.1808. [DOI] [PubMed] [Google Scholar]